Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chaihu Longgu Muli Decoction (CLMD) is a classic Traditional Chinese Medicine (TCM) formula first documented in the 'Shanghan Lun' (Treatise on Febrile Diseases). It is a complex multi-herb decoction traditionally used to treat neuropsychiatric conditions characterized by 'liver qi stagnation' and 'disturbed spirit,' including epilepsy, anxiety, depression, and insomnia. The formula typically consists of Radix Bupleuri (Chaihu), Fossilia Ossis Mastodi (Longgu), Concha Ostreae (Muli), Radix Scutellariae (Huangqin), Rhizoma Pinelliae (Banxia), Zingiber officinale (Shengjiang), Radix et Rhizoma Rhei (Dahuang), Cinnamomum cassia (Guizhi), Poria cocos (Fuling), Panax ginseng (Renshen), and Ziziphus jujuba (Dazao). Modern clinical research, such as studies conducted at Hu'nan Brain Hospital, explores its neuroprotective mechanisms in temporal lobe epilepsy, specifically focusing on its ability to modulate autophagy through exosome-mediated miRNA pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chaihu longgu muli decoction.